NASDAQ:AVTX | Free Cash Flow | Avalo Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2013-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$17.69M
2025-12-31-$14.25M
2025-03-31-$9.46M
2024-12-31-$15.04M
2024-03-31-$6.2M
2023-12-31-$2.77M
2023-03-31-$10.05M
2022-12-31-$3.94M$0.00-$3.94M
2022-03-31-$16.07M$0.00-$16.07M
2021-12-31-$17.1M$11,000.00-$17.11M
2021-03-31-$18.32M$21,000.00-$18.34M
2020-12-31-$14.38M$0.00-$14.38M
2020-03-31-$5.74M$0.00-$5.74M
2019-12-31-$1.68M$2.00-$1.68M-103.66%
2019-03-31-$3.12M$165,969.00-$3.29M
2018-12-31-$1.98M$499,358.00-$2.48M
2018-03-31-$280,423.00$19,224.00-$299,647.00
2017-12-31-$2.55M$15,335.00-$2.56M
2017-03-31-$2.24M$1,801.00-$2.24M
2016-12-31-$3.71M$9,237.00-$3.72M
2016-03-31-$3.71M$8,898.00-$3.72M
2015-12-31-$3.55M$0.00-$3.55M
2015-03-31-$3.07M
2014-12-31-$3.97M$0.00-$3.97M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$51.46M
2024-12-31-$49.06M
2023-12-31-$30.68M
2022-12-31-$26.75M$95,000.00-$26.85M
2021-12-31-$70.89M$113,000.00-$71.01M
2020-12-31-$40.54M$63,000.00-$40.6M
2019-12-31-$19.13M$262,013.00-$19.4M
2018-12-31-$3.13M$564,415.00-$3.69M
2017-12-31$12.58M$23,325.00$12.56M105.78%
2016-12-31-$14.57M$34,883.00-$14.61M
2015-12-31-$10.16M$19,984.00-$10.18M
2014-12-31-$15.52M$19,502.00-$15.54M
2013-12-31-$11.49M$29,268.00-$11.51M